Table 1.
Effect on serum glucose, insulin, biomarkers, and antinociceptive activities against alloxan induced diabetic complications.
| Treatment | Glucose (mmol/L) | Insulin level (μu/mL) | LDH (IU/L) | CK-MB (IU/L) | CK-NAC (IU/L) | Antinociceptive activity |
|
|---|---|---|---|---|---|---|---|
| Hot plate test (s) | Tail immersion test (seconds) | ||||||
| Normal control | 95.57 ± 0.57 | 27.56 ± 0.62 | 96.64 ± 0.57 | 209.53 ± 1.15 | 73.22 ± 0.57 | 6.33 ± 0.28 | 3.66 ± 0.28 |
| Diabetic control | 189.22 ± 0.15c | 9.21 ± 0.24c | 277.1 ± 1.15c | 428.5 ± 2.88c | 175.52 ± 1.15c | 13.66 ± 0.57c | 13.33 ± 0.57c |
| TOL | 138.89 ± 0.57c,e | 19.84 ± 0.59b,e | 137.05 ± 1.15c,e | 342.46 ± 1.73c,e | 125.66 ± 0.57c,e | 9.57 ± 0.28b,e | 8.45 ± 0.57c,e |
| PJ | 143.57 ± 0.57c,e | 15.39 ± 0.73c,e | 146.99 ± 1.1c,e | 375.37 ± 2.30c,e | 142.81 ± 1.15c,e | 10.66 ± 0.57c,d | 10.33 ± 0.17c,d |
| TOL + PJ | 114.25 ± 0.28c,e,h | 23.83 ± 0.19a,e,g | 128.63 ± 0.57c,e,h | 240.37 ± 2.30c,e,h | 80.21 ± 0.28c,e,h | 7.52 ± 0.17e,f | 6.01 ± 0.26a,e,f |
All values are mean ± SEM, n = 8.
ap < 0.05, bp < 0.01, and cp < 0.001, when compared to normal control; dp < 0.01, and ep < 0.001 compared to diabetic control; and fp < 0.05, gp < 0.01 , and hp < 0.001 when compared to TOL alone treated group.
CK-MB, creatinine kinase MB; CK-NAC = creatinine kinase NAC; LDH, lactate dehydrogenase; PJ, pomegranate juice; SEM, standard error of the mean; TOL, tolbutamide.